Novartis AG

Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer (2024) Fasching P, Decker T, Hartkopf A, Nusch A, Heinrich BJ, Kurbacher C, Fuchs R, et al. Journal article Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study. (2024) Passeron T, Reinhardt M, Ehst B, Weiss J, Sluzevich J, Sticherling M, Reygagne P, et al. Journal article Real-World Gait Detection Using a Wrist-Worn Inertial Sensor: Validation Study (2024) Kluge F, Brand YE, Micó-Amigo ME, Bertuletti S, D'Ascanio I, Gazit E, Bonci T, et al. Journal article Regulatory Issues of Platform Trials: Learnings from EU-PEARL (2024) Nguyen QL, Hees K, Hernandez Penna S, König F, Posch M, Bofill Roig M, Meyer EL, et al. Journal article, Review article Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study. (2024) Kaeley GS, Schett G, Conaghan PG, McGonagle D, Behrens F, Goupille P, Gaillez C, et al. Journal article A Survival Analysis Approach to Predicting Severe Leukopenia in Advanced Breast Cancer Patients (2024) Vodenčarević A, Kreuzeder J, Wöckel A, Fasching P Conference contribution Fiber alignment in 3D collagen networks as a biophysical marker for cell contractility (2023) Böhringer D, Bauer A, Moravec I, Bischof L, Kah DTE, Mark C, Grundy TJ, et al. Journal article Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension (2023) D'Agostino MA, Carron P, Gaillez C, Conaghan PG, Naredo E, López-Rdz A, Šenolt L, et al. Journal article Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant (2023) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Assessing real-world gait with digital technology? Validation, insights and recommendations from the Mobilise-D consortium (2023) Micó-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, Kirk C, Soltani A, Küderle A, et al. Journal article